Osteoporosis

Thursday, 11 April 2002

Organizer

 Y. Boutsen (Yvoir, Belgium)  

Corticosteroid-induced osteoporosis, from cell to prevention

Session I

  
Abstract no
Chair Y. Boutsen (Yvoir, Belgium)  
9.45 – 10.30 Glucocorticoid mechanisms of action on bone cells
N. Franchimont (Belgium)		  
10.30 – 10.45 Discussion  
10.45 – 11.15 coffee break  
11.15 – 12.00 Epidemiology of glucocorticoid-induced osteoporosis
T. Van Staa (United Kingdom).		  
12.00 – 12.30 Discussion  
12.30 end of session I  
12.30 – 14.00 lunch and poster viewing  

Session II

 

Abstract no
Chair Y. Boutsen (Yvoir, Belgium)  
15.00 – 15.30 Bisphosphonates as prevention and treatment of gluco-corticoid-induced osteoporosis
J.P. Devogelaer (Brussels, Belgium)		  
15.30 – 16.00 Risedronate is effective and well tolerated in treating corticosteroid-induced osteoporosis
J.P. Devogelaer, S. Adami, and D.M. Reid (Brussels, Belgium)
71
16.00 – 16.30 Practical guidelines for the management of glucocorticoid-induced osteoporosis
C. Roux (France)		  
16.30 –17.00 discussion and final remarks  
17.00 end of workshop 3  
             

Workshop 3  Posters

Abstract no
Risedronate is an effective therapy for men receiving glucocorticoid therapy
J.P. Devogelaer, S. Adami,  and D.M. Reid (Brussels, Belgium)
69
Risedronate prevents corticosteroid-induced bone loss and decreases the risk of vertebral fractures
JP Devogelaer, S. Adami, and D.M. Reid (Brussels, Belgium)
70
Influential factors of low bone mineral density in men with type 2  diabetes mellitus
K. Vartanian,  and A. Ametov (Moscow, Russia)
72
Statins do not improve bone mass in postmenopausal women
A. Laviano, L. Ferrone, I. Preziosa, M. Muscaritoli, Y. Tari, and F. Rossi Fanelli (Rome, Italy) 
73